MorphoSys recently communicated its plans for its proprietary pipeline, which will help transform the company into a fully integrated biopharmaceutical company. It will be commencing Phase II trials for MOR208 in diffuse large B-cell lymphoma (DLBCL) and chronic lymphocytic leukaemia (CLL) over the next six months, with a Phase III trial in DLBCL expected to start in 2017. MOR202 Phase I/IIa trials in multiple myeloma (MM) are ongoing with a Phase III expected to commence in 2017.
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Getting aggressive on its pipeline
MorphoSys recently communicated its plans for its proprietary pipeline, which will help transform the company into a fully integrated biopharmaceutical company. It will be commencing Phase II trials for MOR208 in diffuse large B-cell lymphoma (DLBCL) and chronic lymphocytic leukaemia (CLL) over the next six months, with a Phase III trial in DLBCL expected to start in 2017. MOR202 Phase I/IIa trials in multiple myeloma (MM) are ongoing with a Phase III expected to commence in 2017.